Industry
Repertoire Immune Medicines
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
75.0%
3 terminated/withdrawn out of 4 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
3(100.0%)
3Total
Phase 1(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT07293754Phase 1Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Role: lead
NCT04762225Phase 1Terminated
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
Role: lead
NCT05061940Terminated
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Role: lead
NCT03815682Phase 1Terminated
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Role: lead
All 4 trials loaded